Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Sell
12
PRCT Quote, Financials, Valuation and Earnings
Last price:
$29.14
Seasonality move
:
21.08%
Day range:
$29.12 - $30.67
52-week range:
$27.80 - $76.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.34x
P/B ratio:
4.28x
Volume:
1.2M
Avg. volume:
1.1M
1-year change:
-58.17%
Market cap:
$1.6B
Revenue:
$224.5M
EPS (TTM):
-$1.54
Analysts' Opinion
-
Consensus RatingPROCEPT BioRobotics Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $50.73, PROCEPT BioRobotics Corp. has an estimated upside of 74.14% from its current price of $29.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $38.00 representing 100% downside risk from its current price of $29.13.
Fair Value
-
According to the consensus of 11 analysts, PROCEPT BioRobotics Corp. has 74.14% upside to fair value with a price target of $50.73 per share.
PRCT vs. S&P 500
-
Over the past 5 trading days, PROCEPT BioRobotics Corp. has underperformed the S&P 500 by -4.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PROCEPT BioRobotics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PROCEPT BioRobotics Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PROCEPT BioRobotics Corp. reported revenues of $83.3M.
Earnings Growth
-
PROCEPT BioRobotics Corp. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter PROCEPT BioRobotics Corp. reported earnings per share of -$0.38.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
5.34x
EV / EBIT:
--
EV / Revenue:
4.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-17.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$190.4M
Return On Assets:
-17.25%
Net Income Margin (TTM):
-28.2%
Return On Equity:
-23.51%
Return On Invested Capital:
-19.24%
Operating Margin:
-27.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $116.4M | $199.8M | $299.9M | $58.4M | $83.3M | |
| Gross Profit | $57.7M | $109.6M | $190.4M | $35.6M | $52.4M | |
| Operating Income | -$104.7M | -$106.5M | -$92.5M | -$22.4M | -$23.2M | |
| EBITDA | -$100.4M | -$101.4M | -$86.4M | -$21.1M | -$21.6M | |
| Diluted EPS | -$2.33 | -$1.95 | -$1.54 | -$0.40 | -$0.38 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $339.5M | $288.9M | $368.7M | $323M | $454.2M | |
| Total Assets | $351.5M | $324M | $421.1M | $374.1M | $511.5M | |
| Current Liabilities | $14.2M | $27.4M | $41.4M | $53.6M | $53.9M | |
| Total Liabilities | $68.2M | $103.3M | $121.8M | $132.9M | $131.3M | |
| Total Equity | $283.3M | $220.8M | $299.4M | $241.2M | $380.3M | |
| Total Debt | $52.3M | $74.1M | $78M | $78.8M | $76.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$108.4M | -$91.6M | -$71M | -$18.8M | -$6.6M | |
| Cash From Investing | -$17.4M | -$12M | -$8.7M | -$246K | -$2.9M | |
| Cash From Financing | $163.6M | $12.5M | $177.3M | $1.7M | $1.1M | |
| Free Cash Flow | -$125.7M | -$103.6M | -$79.7M | -$19M | -$9.5M | |
PRCT
Sector
Market Cap
$1.6B
$25.9M
Price % of 52-Week High
38.13%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-8.87%
-1.66%
1-Year Price Total Return
-58.17%
-18.99%
Beta (5-Year)
--
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$30.49
200-day SMA
Sell
Level
$43.77
Bollinger Bands (100)
Sell
Level
31.02 - 36.92
Chaikin Money Flow
Sell
Level
-1.2M
20-day SMA
Sell
Level
$31.78
Relative Strength Index (RSI14)
Sell
Level
37.70
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-99.8408
50-day SMA
Sell
Level
$32.10
MACD (12, 26)
Buy
Level
2.32
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-1.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.413)
Buy
CA Score
(Annual)
Level (-0.1609)
Sell
Beneish M-Score
(Annual)
Level (-1.7031)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-0.0078)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.
Stock Forecast FAQ
In the current month, PRCT has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The PRCT average analyst price target in the past 3 months is $50.73.
-
Where Will PROCEPT BioRobotics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PROCEPT BioRobotics Corp. share price will rise to $50.73 per share over the next 12 months.
-
What Do Analysts Say About PROCEPT BioRobotics Corp.?
Analysts are divided on their view about PROCEPT BioRobotics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PROCEPT BioRobotics Corp. is a Sell and believe this share price will drop from its current level to $38.00.
-
What Is PROCEPT BioRobotics Corp.'s Price Target?
The price target for PROCEPT BioRobotics Corp. over the next 1-year time period is forecast to be $50.73 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PRCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PROCEPT BioRobotics Corp. is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRCT?
You can purchase shares of PROCEPT BioRobotics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PROCEPT BioRobotics Corp. shares.
-
What Is The PROCEPT BioRobotics Corp. Share Price Today?
PROCEPT BioRobotics Corp. was last trading at $29.14 per share. This represents the most recent stock quote for PROCEPT BioRobotics Corp.. Yesterday, PROCEPT BioRobotics Corp. closed at $29.13 per share.
-
How To Buy PROCEPT BioRobotics Corp. Stock Online?
In order to purchase PROCEPT BioRobotics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PRCT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PRCT
Sector
P/E ratio
--
23.82x
PEG ratio
--
-0.01x
P/B ratio
4.28x
1.83x
Price / LTM sales
5.34x
1.56x
Growth Metrics
PRCT
Sector
Revenue growth
42.76%
4.18%
Earnings growth
4.74%
9.66%
Revenue (5-year growth)
105.21%
6.28%
Earnings forecast
-$0.32
-$0.18
Profitability
PRCT
Sector
Profitability FY 2024
$137.1M
$3.1M
Return on invested capital
-19.24%
-32.89%
Return on assets
-17.25%
-29.56%
Return on equity
-23.51%
-38.66%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
3
Balance Sheet
PRCT
Sector
Total cash
$294.3M
$25.2M
Short term investments
--
$25.1M
Total assets
$534M
$73M
Long term debt
$76.8M
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Will Data Centers Be In Space?
With demand for data centers seemingly growing by the day,…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
56
INTC alert for Jan 26
Intel Corp. [INTC] is down 2.31% over the past day.
Buy
64
BNR alert for Jan 22
Burning Rock Biotech Ltd. [BNR] is down 0% over the past day.
Sell
19
APGE alert for Jan 26
Apogee Therapeutics, Inc. [APGE] is down 1.3% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
